The FTC Says the Most Influential Transgender-Care Guideline in America Was Built on Evidence It Couldn’t Show.

On June 17, 2026, the Federal Trade Commission and four state attorneys general sued the World Professional Association for Transgender Health (WPATH) — the body whose “Standards of Care” guide clinicians, insurers, and courts across the country. The complaint, filed in the U.S. District Court for the Northern District of Texas, alleges WPATH deceived parents into believing its pediatric gender-transition guidelines “are based on strong evidence derived from scientific methods” when, the FTC says, they are not.

FTC Chairman Andrew Ferguson (R) framed it as a consumer-protection action, not a medical ruling: “Parents have a right to make informed decisions about their children’s health.” The states of Alaska, Iowa, Nebraska, and Texas — all with Republican attorneys general — joined. The commission’s vote to authorize the complaint was 2–0.

Read carefully, this is an allegation, not a verdict. WPATH calls the suit “baseless” and “pure retaliation,” and a federal judge had already, in May, temporarily blocked an earlier FTC probe on First Amendment grounds. What the case puts on trial is something narrower and more consequential than any one treatment: the evidence base beneath a guideline that much of American medicine has treated as settled.

• June 17, 2026 — the date the FTC and four states filed suit against WPATH in the Northern District of Texas · Source: FTC press release; The Hill
• 2–0 — the FTC commission vote authorizing staff to file the complaint · Source: FTC press release
• 4 states — Alaska, Iowa, Nebraska, and Texas joined the FTC as co-plaintiffs · Source: FTC press release; STAT News
• "Very low" certainty — how the 2025 HHS umbrella review graded the evidence on psychological outcomes of pediatric gender medicine · Source: HHS evidence review
• SOC-8 · 2022 — WPATH's eighth edition Standards of Care — the document at the center of the FTC's claims about removed age minimums · Source: FTC complaint; Fox News

The FTC’s theory is consumer-protection law, not medicine. Its complaint alleges that WPATH — through its Standards of Care — gave clinicians the means to make “false and unsubstantiated claims” to parents in order to sell pediatric transition services, misrepresenting the medical consensus, the medical necessity, and the safety and effectiveness of those services in violation of the FTC Act. The agency contends WPATH labeled nearly every pediatric transition service “medically necessary” — a designation that, the complaint says, was calibrated to maximize the odds that insurers would pay, rather than to reflect proven need.

The most striking allegation in the FTC’s telling: that clinicians, drawing on WPATH’s framing of these treatments as “lifesaving,” sometimes asked parents whether they “would rather have a live daughter or a dead son” — even though, the complaint states, there is no competent and reliable scientific evidence that the interventions reduce suicide risk. WPATH disputes this characterization root and branch. Every line in this section is the government’s allegation; none has been tested at trial.

Keep Reading

Society · TDS Watch

Rosie O'Donnell Told Jim Acosta the 2024 Election Was Stolen and Trump Will Cancel the Midterms — With No Evidence

Read →

WPATH’s eighth edition of the Standards of Care — SOC-8, published in 2022 — is the spine of the case. The FTC alleges that a 2021 draft included suggested minimum ages for certain hormonal and surgical interventions, and that those age minimums were stripped from the published version. According to the complaint, that change was not driven by new medical evidence. The 2024 Cass Review in the United Kingdom — the largest independent review of youth gender services — reached a parallel conclusion about the underlying literature, finding the evidence for puberty blockers and cross-sex hormones in minors to be “remarkably weak,” and led NHS England to restrict puberty blockers outside clinical trials.

Much of the documentary backbone for the evidence-base critique surfaced not through the FTC but through civil litigation: Boe v. Marshall, the challenge to Alabama’s ban on pediatric transition. In discovery, internal WPATH communications became public. Critics — and now the FTC — point to those emails as showing that WPATH commissioned systematic reviews of treatment outcomes through Johns Hopkins, then constrained their publication when the findings did not support its preferred recommendations. Other exchanges, critics say, show WPATH consulting with litigation-minded advocates over how SOC-8 would read in court, and SOC-8’s lead author, Eli Coleman, testifying in a deposition that the no-age-minimum recommendation did not reach consensus among the guideline authors.

WPATH’s defenders read the same record very differently — as the ordinary, messy work of drafting clinical guidance, selectively quoted by litigants with a stake in banning the care. That dispute over what the emails mean is, in effect, what the FTC is now asking a court to resolve. We present the allegations as allegations.

Keep Reading

Society · TDS Watch

Amanda Seyfried Called Charlie Kirk 'Hateful' — Now She Wants the Nuance She Refused Him

Read →

“The FTC alleges WPATH deceived consumers into believing its treatment guidelines are based on strong evidence derived from scientific methods.”

Federal Trade Commission — Complaint summary, June 17, 2026

The piece of the story that lands it squarely in the accountability lane is the claim — drawn from the Alabama emails and now echoed in the FTC complaint — that the age-minimum removal followed pressure from Adm. Rachel Levine (D), who served as the Biden administration’s Assistant Secretary for Health. Critics say the emails show Levine’s office urging WPATH to drop the age limits over concern they could be used against the administration’s policy goals — in other words, that a federal official’s political calculation, not a clinical one, helped shape a guideline doctors nationwide would follow.

This is contested ground, and fairness requires the caveat: the characterization of those emails comes from parties litigating against the care, and Levine and WPATH reject the framing. But the underlying documents are real court exhibits, and the U.S. Senate HELP Committee, under Ranking Member — later Chairman — Bill Cassidy (R-LA), opened its own investigation into how medical bodies set these guidelines. The HHS evidence review released in 2025 reached the same destination from a different road: it graded the certainty of the evidence for psychological benefit as “very low.”

WPATH has not conceded an inch, and its case deserves to be stated plainly. The organization calls the complaint “baseless” and argues the FTC “is not a medical provider and has no place interfering with the process of individualized medical decision-making.” It says its Standards of Care exist precisely to support care “tailored to individual patients,” not a one-size-fits-all protocol, and that “transgender and gender-diverse patients deserve the highest level of care from their medical professionals.” WPATH frames the suit as “pure retaliation” in a broader federal campaign against gender-affirming care — and notes that a federal judge in May temporarily blocked the FTC’s earlier investigation on First Amendment grounds.

WPATH’s scientific defenders also contest the Cass Review and the HHS report directly, arguing the umbrella-review method discounts real-world clinical evidence and that “low-certainty” is a technical grade common across pediatric medicine, not proof of harm. Major medical associations have historically endorsed WPATH’s framework. The reader should weigh both the critique and this rebuttal — the question a court will decide is not whether the care is good or bad, but whether WPATH’s claims about its evidence crossed into deception.

WPATH’s Standards of Care are not an obscure document. Clinicians cite them to justify treatment, insurers cite them to decide coverage, and litigants on both sides cite them in court. If the FTC prevails, it would mark the first time a U.S. agency formally treated the guideline’s evidentiary claims as a deceptive-practices matter — with ripple effects for the American Academy of Pediatrics and the Endocrine Society, both of which the FTC has also investigated and both of which have sued in response. If WPATH prevails, the First Amendment limits on second-guessing professional medical guidance would be reaffirmed.

The honest bottom line: this is an inquiry with real documentary weight behind it — the Cass Review, the HHS evidence review, the Boe v. Marshall emails, and a 2–0 commission vote — but it is still an inquiry. No court has found WPATH deceived anyone. What is settled is the question worth watching: whether the evidence under one of medicine’s most consequential guidelines is as solid as the institutions relying on it have assumed. We will track the case as it moves through the Northern District of Texas.

More From Civic Intelligence

Society · Crime Problem

An MMA Fighter's Decoy Sting Helped Police Arrest a Florida Student-Government Leader — and His Committee Voted Him Out

Retired MMA fighter Dustin 'Scrappy' Lampros and his 561 Predator Catchers group say their decoy set…

Society · Accountability

Ilhan Omar's Husband Reported Income as Low as $200 Last Year

Rep. Ilhan Omar's (D-MN) husband Tim Mynett — whose firm E Street Group collected nearly $3 million…

Last updated June 21, 2026